This is a Phase IIa, sequential assignment, non- randomized, open-label treatment study to determine the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of camizestrant in combination with atirmociclib.
The single-arm study includes:
* Screening period
* Atirmociclib single dose period
* Doublet intervention period
* Post-treatment follow-up period
